RNS Number : 6523J
EKF Diagnostics Holdings PLC
25 August 2021
 

 

 

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Notice of Results

Investor briefing

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its interim results for the six months ended 30 June 2021 on Tuesday 14 September 2021.

 

Investor briefing

EKF Diagnostics will be hosting a live online presentation open to all investors on Wednesday 15 September 2021 at 5.15 pm (BST), via video conference call. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email ekf@walbrookpr.com. 

 

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Christopher Mills, Non-executive Chairman

Tel: +44 (0) 29 2071 0570

Julian Baines, CEO


Richard Evans, FD & COO




Singer Capital Markets

Tel: 020 7496 3000

Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)




Walbrook PR Limited

Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com  

Paul McManus / Lianne Cawthorne

Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303 

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORFZGZRKDZGMZM
admin Notice of Results 32078389 A Wed, 08/25/2021 - 07:00 LSE RNS Advance Notice of Results EKF